Q2 2024 · 13F-HR
Atle Fund Management ABholdings as filed
Filed 2024-08-14 · accession 0001381843-24-000006
$164.0M
Reported value
38
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 532457108 | LLY | ELI LILLY & CO | $24.6M | 15.0% | 27,144 | Common | SOLE |
| 91324P102 | UNH | UFP TECHNOLOGIES INC | $16.1M | 9.84% | 31,680 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $14.0M | 8.51% | 112,734 | Common | SOLE |
| 883556102 | TMO | THERMO FISHER SCIENTIFIC INC | $10.8M | 6.56% | 19,458 | Common | SOLE |
| 031162100 | AMGN | AMGEN INC | $8.6M | 5.26% | 27,589 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $8.2M | 5.00% | 106,557 | Common | SOLE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $7.2M | 4.42% | 6,893 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $7.1M | 4.31% | 15,095 | Common | SOLE |
| 03073E105 | COR | CENCORA INC | $6.8M | 4.17% | 30,320 | Common | SOLE |
| 863667101 | SYK | STRYKER CORPORATION | $6.8M | 4.15% | 19,983 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $6.1M | 3.73% | 35,618 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $3.9M | 2.38% | 34,483 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $3.4M | 2.06% | 36,505 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $3.3M | 1.98% | 23,630 | Common | SOLE |
| 46266C105 | IQV | IQVIA HLDGS INC | $3.0M | 1.80% | 13,984 | Common | SOLE |
| 60855R100 | MOH | MOLINA HEALTHCARE INC | $2.8M | 1.72% | 9,500 | Common | SOLE |
| 14149Y108 | CAH | CARDINAL HEALTH INC | $2.7M | 1.65% | 27,500 | Common | SOLE |
| 902673102 | UFPT | UFP TECHNOLOGIES INC | $2.6M | 1.58% | 9,800 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $2.6M | 1.57% | 75,200 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $2.5M | 1.50% | 35,841 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $1.9M | 1.18% | 40,691 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $1.8M | 1.11% | 30,837 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $1.8M | 1.08% | 39,100 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $1.7M | 1.01% | 68,800 | Common | SOLE |
| 68404L201 | OPCH | OPTION CARE HEALTH INC | $1.5M | 0.92% | 54,395 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $1.5M | 0.90% | 148,207 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $1.5M | 0.89% | 75,794 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $1.4M | 0.85% | 7,624 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $1.4M | 0.83% | 53,432 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $1.2M | 0.76% | 22,496 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $1.1M | 0.64% | 34,900 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $805,836 | 0.49% | 23,778 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $786,984 | 0.48% | 226,145 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HLDG INC | $688,179 | 0.42% | 20,199 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $645,366 | 0.39% | 34,328 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $609,479 | 0.37% | 143,407 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $481,121 | 0.29% | 64,321 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $371,649 | 0.23% | 184,900 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.